The oral JAK inhibitor was approved for treating AD earlier in 2021 for treating AD in the United Kingdom, Japan, and Korea, and is under review at the US Food and Drug Administration.
Interruption of 4-6 cyclin D-dependent kinase inhibitors (CDK4/6i) was associated with a high rate of progression among women with metastatic breast cancer, particularly those with liver metastases.
Patients who received elacestrant demonstrated a clinically meaningful improvement in progression-free survival as compared to those who received standard of care.
COSMOS trial results in patients with psoriatic arthritis fit with the expectation that "people who ve previously failed a TNF inhibitor might be a little less likely to respond to guselkumab."
What if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That s one possibility for a Merck agent in the earliest stages of human trials.